Dry coated tablet
AssigneeTakeda Pharmaceutical Company Limited
InventorsTetsuya Kawano, Yasushi Mima, Yumiko Ishii
Life of this patent
Estimating the term…
Abstract
Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains enteric micro granules containing a proton pump inhibitor.
Claims3
A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet comprising acetylsalicylic acid, and the outer layer comprises enteric micro granules comprising a proton pump inhibitor;
- the enteric coating in the inner core comprises a methacrylic acid copolymer LD and an ethyl acrylate-methyl methacrylate copolymer;
- and
- a content ratio of the methacrylic acid copolymer LD and the ethyl acrylate-methyl methacrylate copolymer is 85:15 - 95:5.
A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet comprising acetylsalicylic acid, and the outer layer comprises enteric micro granules comprising a proton pump inhibitor;
- and
- a difference in the diameter between the inner core and the dry coated tablet is not less than 2.0 mm before enteric coating of the inner core.
A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet comprising acetylsalicylic acid, and the outer layer comprises enteric micro granules comprising a proton pump inhibitor;
- and
- a weight ratio of the inner core and the outer layer is 1:2 - 1:6.
Dependencies are inferred from the claim text.